Clinical Trials Logo

Clinical Trial Summary

Lactoferrin (Lf) is a mammalian cationic iron binding glycoprotein belonging to the transferrin family which was discovered 70 years ago, and isolated simultaneously from human and bovine milks in 1960. It is widely distributed in all biological fluids and is also expressed by immune cells, which release it under stimulation by pathogens


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04267653
Study type Interventional
Source Assiut University
Contact
Status Completed
Phase Phase 4
Start date January 1, 2018
Completion date October 30, 2018

See also
  Status Clinical Trial Phase
Completed NCT05153278 - IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department
Withdrawn NCT05073562 - Nutrition Intervention to Address Anemia Among Adolescent Girls in Liberia N/A
Completed NCT04631679 - Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers (WASH-OUT)
Completed NCT05673161 - Retrospective Evaluation of the Effect of Iron (Fe) Infusion on Complications in Anemic Patients Undergoing Thoracotomy
Completed NCT04915820 - Iron and COVID-19 Vaccine Response N/A
Completed NCT04912661 - Iron and Vaccine Response N/A
Recruiting NCT04793906 - Meals to Improve Absorption of Iron Supplements N/A
Completed NCT05314062 - Effect of Iron Source on the Growth of Enteric Pathogens N/A
Recruiting NCT06238895 - Optimizing Dosing Strategies in Oral Iron Supplementation Phase 4
Completed NCT04705662 - GI Effects of Iron in Healthy Volunteers N/A
Completed NCT05762380 - Effect of Iron Supplements on the Growth of Enteric Pathogens N/A
Completed NCT04744181 - Patient Blood Management In CARdiac sUrgical patientS
Active, not recruiting NCT05545527 - Neuroimaging Ancillary Study
Terminated NCT03610230 - Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients N/A
Completed NCT01227616 - Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis Phase 4